Characterization of Early Inflammatory Events Leading to Provoked Vulvodynia Development in Rats.
glutamate
hyperinnervation
inflammation
mast cell
nerve growth factor
provoked vulvodynia
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
03
2022
accepted:
16
06
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Provoked vulvodynia (PV) is the main cause of vulvar pain and dyspareunia. The etiology of PV has not yet been elucidated. However, PV is associated with a history of recurrent inflammation, and its often accompanied by increases in the numbers of mast cells (MCs) and sensory hyperinnervation in the vulva. Therefore, this study aimed to examine the role of MCs and the early inflammatory events in the development of chronic vulvar pain in a rat model of PV. Mechanical and thermal vulvar sensitivity was measured for 5 months following zymosan vulvar challenges. Vulvar changes in glutamate and nerve growth factor (NGF) were analyzed using ELISA. Immunofluorescence (IF) staining of the vulvar section after 20, 81, and 160 days of the zymosan challenge were performed to test MCs accumulation, hyperinnervation, and expression of pain channels (transient receptor potential vanilloid/ankyrin-1-TRPV1 & TRPA1) in vulvar neurons. Changes in the development of vulvar pain were evaluated following the administration of the MCs stabilizer ketotifen fumarate (KF) during zymosan vulvar challenges. Zymosan-challenged rats developed significant mechanical and thermal vulvar sensitivity that persisted for over 160 days after the zymosan challenge. During inflammation, increased local concentrations of NGF and glutamate and a robust increase in MCs degranulation were observed in zymosan-challenged rats. In addition, zymosan-challenged rats displayed sensory hyperinnervation and an increase in the expression of TRPV1 and TRPA1. Treatment with KF attenuated the upregulated level of NGF during inflammation, modulated the neuronal modifications, reduced MCs accumulation, and enhanced mechanical hypersensitivity after repeated inflammation challenges. The present findings suggest that vulvar hypersensitivity is mediated by MCs accumulation, nerve growth, and neuromodulation of TRPV1 and TRPA1. Hence, KF treatment during the critical period of inflammation contributes to preventing chronic vulvar pain development.
Sections du résumé
Background
UNASSIGNED
Provoked vulvodynia (PV) is the main cause of vulvar pain and dyspareunia. The etiology of PV has not yet been elucidated. However, PV is associated with a history of recurrent inflammation, and its often accompanied by increases in the numbers of mast cells (MCs) and sensory hyperinnervation in the vulva. Therefore, this study aimed to examine the role of MCs and the early inflammatory events in the development of chronic vulvar pain in a rat model of PV.
Methods
UNASSIGNED
Mechanical and thermal vulvar sensitivity was measured for 5 months following zymosan vulvar challenges. Vulvar changes in glutamate and nerve growth factor (NGF) were analyzed using ELISA. Immunofluorescence (IF) staining of the vulvar section after 20, 81, and 160 days of the zymosan challenge were performed to test MCs accumulation, hyperinnervation, and expression of pain channels (transient receptor potential vanilloid/ankyrin-1-TRPV1 & TRPA1) in vulvar neurons. Changes in the development of vulvar pain were evaluated following the administration of the MCs stabilizer ketotifen fumarate (KF) during zymosan vulvar challenges.
Results
UNASSIGNED
Zymosan-challenged rats developed significant mechanical and thermal vulvar sensitivity that persisted for over 160 days after the zymosan challenge. During inflammation, increased local concentrations of NGF and glutamate and a robust increase in MCs degranulation were observed in zymosan-challenged rats. In addition, zymosan-challenged rats displayed sensory hyperinnervation and an increase in the expression of TRPV1 and TRPA1. Treatment with KF attenuated the upregulated level of NGF during inflammation, modulated the neuronal modifications, reduced MCs accumulation, and enhanced mechanical hypersensitivity after repeated inflammation challenges.
Conclusion
UNASSIGNED
The present findings suggest that vulvar hypersensitivity is mediated by MCs accumulation, nerve growth, and neuromodulation of TRPV1 and TRPA1. Hence, KF treatment during the critical period of inflammation contributes to preventing chronic vulvar pain development.
Identifiants
pubmed: 35845089
doi: 10.2147/JIR.S367193
pii: 367193
pmc: PMC9286136
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3901-3923Informations de copyright
© 2022 Awad-Igbaria et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest in relation to this work.
Références
EMBO J. 2005 Dec 21;24(24):4211-23
pubmed: 16319926
Blood. 2013 Sep 12;122(11):1853-62
pubmed: 23775718
Clin J Pain. 2011 Nov-Dec;27(9):755-63
pubmed: 21593667
J Low Genit Tract Dis. 2019 Jan;23(1):58-64
pubmed: 30418350
Int J Womens Health. 2014 May 02;6:437-49
pubmed: 24833921
Mol Pain. 2020 Jan-Dec;16:1744806920914204
pubmed: 32189565
Neuron. 2002 Sep 26;36(1):57-68
pubmed: 12367506
J Dent Res. 2007 Jun;86(6):550-5
pubmed: 17525356
Immunol Rev. 2018 Mar;282(1):168-187
pubmed: 29431216
F1000Res. 2016 Oct 26;5:2581
pubmed: 27853523
Biol Reprod. 2014 Dec;91(6):144
pubmed: 25359899
J Womens Health (Larchmt). 2014 Aug;23(8):649-56
pubmed: 25046165
J Pain Res. 2020 May 26;13:1223-1241
pubmed: 32547184
Semin Reprod Med. 2015 Jul;33(4):239-45
pubmed: 26132928
Ann Epidemiol. 2009 Nov;19(11):771-7
pubmed: 19825458
Nat Med. 2010 Nov;16(11):1267-76
pubmed: 20948535
J Pain Res. 2016 Oct 03;9:757-762
pubmed: 27757050
J Clin Invest. 2005 Sep;115(9):2393-401
pubmed: 16110328
J Neuroimmunol. 2004 Aug;153(1-2):171-82
pubmed: 15265675
Environ Health Perspect. 2001 Aug;109 Suppl 4:567-71
pubmed: 11544165
Adv Pharm Bull. 2015 Jun;5(2):217-22
pubmed: 26236660
Br J Pharmacol. 2020 Sep;177(18):4223-4241
pubmed: 32579702
Am J Obstet Gynecol. 2015 Apr;212(4):476.e1-8
pubmed: 25448516
Dis Model Mech. 2013 Jul;6(4):889-95
pubmed: 23828645
Front Cell Infect Microbiol. 2021 Jun 17;11:678961
pubmed: 34222047
Biochim Biophys Acta. 2012 Jan;1822(1):74-84
pubmed: 21496484
Front Neurosci. 2019 Sep 19;13:1009
pubmed: 31607850
Int J Environ Res Public Health. 2021 Jun 21;18(12):
pubmed: 34205495
Microb Pathog. 2019 Nov;136:103696
pubmed: 31449855
Pain Rep. 2021 Jun 03;6(2):e902
pubmed: 34104835
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3739-43
pubmed: 8170980
J Histochem Cytochem. 2014 Oct;62(10):698-738
pubmed: 25062998
Pain. 2017 Sep;158(9):1754-1764
pubmed: 28621704
Neuron. 2007 Aug 2;55(3):353-64
pubmed: 17678850
Mol Immunol. 2015 Jan;63(1):38-44
pubmed: 24666768
Pain. 2014 Sep;155(9):1696-1701
pubmed: 24858303
Front Immunol. 2015 May 18;6:238
pubmed: 26042121
J Am Osteopath Assoc. 2019 Mar 01;119(3):164-172
pubmed: 30801112
Sex Med. 2019 Jun;7(2):227-234
pubmed: 30954496
Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R534-47
pubmed: 20032263
Int J Gynecol Pathol. 1998 Jan;17(1):7-11
pubmed: 9475185
Am J Obstet Gynecol. 2016 Dec;215(6):768.e1-768.e8
pubmed: 27457118
Int J Womens Health. 2017 Sep 11;9:631-642
pubmed: 28979166
PLoS One. 2013 Oct 25;8(10):e78673
pubmed: 24205293
Biores Open Access. 2020 Feb 21;9(1):13-21
pubmed: 32117596
J Neurochem. 2014 Dec;131(6):712-30
pubmed: 25270665
J Pain Res. 2019 Apr 29;12:1359-1369
pubmed: 31118754
Curr Opin Allergy Clin Immunol. 2018 Oct;18(5):411-416
pubmed: 30020258
APMIS. 2015 May;123(5):452-6
pubmed: 25912132
Clin Exp Allergy. 1999 May;29(5):695-702
pubmed: 10231325
PLoS One. 2017 Feb 3;12(2):e0169672
pubmed: 28158195
Lancet. 2007 Jun 9;369(9577):1961-71
pubmed: 17560449
J Toxicol Environ Health A. 2001 Oct 26;64(4):311-25
pubmed: 11693490
Biochim Biophys Acta. 2012 Jan;1822(1):21-33
pubmed: 21185371
Eur J Pain. 2004 Apr;8(2):129-33
pubmed: 14987622
Am J Obstet Gynecol. 2002 Sep;187(3):589-94
pubmed: 12237632
Front Cell Neurosci. 2021 Jun 10;15:665066
pubmed: 34177465
Sci Transl Med. 2011 Sep 21;3(101):101ra91
pubmed: 21937756
Am J Sports Med. 2000 Sep-Oct;28(5):725-31
pubmed: 11032232
Int J Gynecol Pathol. 2008 Jan;27(1):136-41
pubmed: 18156988
Obstet Gynecol. 2016 Apr;127(4):745-751
pubmed: 27008217
J Sex Med. 2014 Dec;11(12):3064-71
pubmed: 25174699
Mol Pain. 2008 Nov 14;4:56
pubmed: 19014600